Condition: Advanced Solid Tumour · Sponsor: Nanjing Leads Biolabs Co.,Ltd
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
This description comes directly from the study's public registry record.
Jian zhou · 021-64041990 · maxy@leadsbiolabs.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Guangxi Medical University | Nanning, Guangxi, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Xiangyang Central Hospital | Xiangyang, Hubei, China | Recruiting |
| Jiangxi Cancer Hospital | Nanchang, Jiangxi, China | Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Not Yet Recruiting |
| Zhongshan Hospital of Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| Sir Run Run Shaw Hospital (SRRSH) Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07111546